ClinicalTrials.gg
CompletedNCT06584916Updated Jun 4, 2026

A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MAINTAIN)

A Phase 3 interventional study of Orforglipron and Placebo in Obesity and Overweight, sponsored by Eli Lilly and Company. Completed at 29 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-04.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
376
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies testing orforglipron in Obesity — 4 open to participants now, 10 under way, 9 of them phase 3. orforglipron · Obesity.

Enrollment
11th of 22
376 · median 324
Started
2024
with 5 others
Phase 3
14 of 22
3 open now
Registered
11th of 22
by date
Lead sponsor
21 of 22
Eli Lilly and Company

Among the 22 studies testing orforglipron in Obesity, this one is the 11th largest by enrollment, is one of 6 that started in 2024, is one of 14 in phase 3, and was the 11th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

4 of the 22 studies testing orforglipron in Obesity are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About orforglipron

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing orforglipron in Obesity, or all of them as a file.
02

Study summary

The main purpose of this study is to evaluate the efficacy and safety of orforglipron on maintenance of body weight reduction in participants who previously completed treatment with injectable tirzepatide (Zepbound) or injectable semaglutide (Wegovy) in the SURMOUNT-5 trial (NCT05822830).

Read the detailed description

All enrolled participants will have completed SURMOUNT-5 (I8F-MC-GPHJ; NCT05822830) on treatment and meet further eligibility and randomization criteria. SURMOUNT-5 randomized participants to either injectable tirzepatide (Zepbound) or injectable semaglutide (Wegovy); therefore, all ATTAIN-MAINTAIN participants had prior exposure to one of these injectable incretin-based therapies before transitioning directly to orforglipron 12 mg capsule or placebo. All endpoints for this study will be evaluated separately per each intervention arm of SURMOUNT-5.

03

Conditions studied

  • Obesity
  • Overweight

Keywords

  • Maintenance
  • Weight maintenance
  • Body weight changes
  • Weight loss
  • Incretins
  • Hormones
  • Hormone substitutes
  • Hormone antagonists
  • Physiological effects of drugs
  • tirzepatide
  • semaglutide
  • Zepbound
  • Wegovy
  • injectable GLP-1
  • oral GLP-1
  • incretin therapy
  • GLP-1 receptor agonist
  • crossover from injectable
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have completed the SURMOUNT-5 study (NCT05822830; a trial of injectable tirzepatide [Zepbound] versus injectable semaglutide [Wegovy]) on study treatment

Exclusion criteria

Exclusion Criteria:

  • Have Type 1 Diabetes, Type 2 Diabetes, or any other types of diabetes, history of ketoacidosis, or hyperosmolar state/coma
  • Have a prior or planned surgical treatment for obesity
  • Have acute or chronic hepatitis
  • Have a history of acute or chronic pancreatitis
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
376 participants (actual)

Study arms

  • Experimental
    Orforglipron

    Participants will receive orforglipron orally

    Drug: Orforglipron

  • Placebo comparator
    Placebo

    Participants will receive placebo orally

    Drug: Placebo

Interventions

  • Administered orally

  • DrugPlacebo

    Administered orally

06

What researchers measure

Primary outcomes

  1. Percent Maintenance of Body Weight Reduction Achieved in SURMOUNT-5

    Time frame: Week 52

Secondary outcomes

  1. Percent Change from SURMOUNT-5 Baseline in Body Weight Prior to Start of Treatment

    Time frame: Week 52

  2. Number of Participants Maintaining ≥80% of the Body Weight Reduction Achieved in SURMOUNT-5

    Time frame: Week 52

  3. Change from Baseline in Body Weight

    Time frame: Baseline, Week 52

  4. Change from Baseline in Waist Circumference

    Time frame: Baseline, Week 52

  5. Percent Maintenance of Body Weight Reduction Achieved in SURMOUNT-5

    Time frame: Week 24

07

Study locations

29 sites
  • Cahaba Research
    Birmingham, Alabama 35242, United States
  • Cahaba Research - Pelham
    Pelham, Alabama 35124, United States
  • Southern California Dermatology, Inc.
    Santa Ana, California 92701, United States
  • Encompass Clinical Research
    Spring Valley, California 91978, United States
  • University Clinical Investigators, Inc.
    Tustin, California 92780, United States
  • New Horizon Research Center
    Miami, Florida 33165, United States
  • Rophe Adult and Pediatric Medicine/SKYCRNG
    Union City, Georgia 30291, United States
  • Rocky Mountain Clinical Research
    Idaho Falls, Idaho 83404, United States
  • Iowa Diabetes and Endocrinology Research Center
    West Des Moines, Iowa 50265, United States
  • L-MARC Research Center
    Louisville, Kentucky 40213, United States
  • Arcturus Healthcare , PLC, Troy Internal Medicine Research Division
    Troy, Michigan 48098, United States
  • Prime Health and Wellness/SKYCRNG
    Fayette, Mississippi 39069, United States
  • StudyMetrix Research
    City of Saint Peters, Missouri 63303, United States
  • Palm Research Center Tenaya
    Las Vegas, Nevada 89128, United States
  • Palm Research Center Sunset
    Las Vegas, Nevada 89148, United States
  • Weill Cornell Medical College
    New York, New York 10021, United States
  • PharmQuest Life Sciences, LLC
    Greensboro, North Carolina 27408, United States
  • Lillestol Research
    Fargo, North Dakota 58104, United States
  • Alliance for Multispecialty Research, LLC
    Norman, Oklahoma 73069, United States
  • Tribe Clinical Research, LLC
    Greenville, South Carolina 29607, United States
  • WR-Clinsearch, LLC
    Chattanooga, Tennessee 37421, United States
  • The University of Texas Health Science Center at Houston
    Bellaire, Texas 77401, United States
  • Velocity Clinical Research, Dallas
    Dallas, Texas 75230, United States
  • North Texas Endocrine Center
    Dallas, Texas 75231, United States
  • Biopharma Informatic, LLC
    Houston, Texas 77043, United States
  • PlanIt Research, PLLC
    Houston, Texas 77079, United States
  • Southern Endocrinology Associates
    Mesquite, Texas 75149, United States
  • Puerto Rico Medical Research
    Ponce, 00717, Puerto Rico
  • Wellness clinical Research Vega Baja
    Vega Baja, 00694, Puerto Rico
08

References and documents

Publications

  • Aronne LJ, Horn DB, le Roux CW, Chao AM, Ho W, Halpern B, Griffin R, Xie C, Valderas EG, Lee CJ, Ribeiro A, Hyman DM, Glass L, Xavier N. Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial. Nat Med. 2026 May 13. doi: 10.1038/s41591-026-04386-7. Online ahead of print. PubMed 42120723 ↗

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication or approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2024 to primary completion in Nov 2025, 14 months.

Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's 14 months is below that.

Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 3, 2024
First posted
Sep 5, 2024
StartActual
Sep 13, 2024
Primary completionActual
Nov 21, 2025
CompletionActual
Nov 21, 2025
Last update
Jun 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06584916
Responsible party
Sponsor
First posted
Sep 5, 2024
Start date
Sep 13, 2024
Primary completion
Nov 21, 2025
Completion
Nov 21, 2025
Last update
Jun 4, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Orforglipron

Start the discussion